Arthritis Care & Research · 2022 · 24 citations · 32 references
MedicineClinical SciencesEvidence-based PracticeGood Clinical PracticeRheumatologyPsoriatic ArthritisSystematic ReviewClinical Evidence ReviewClinical Guideline ImplementationClinical Practice Guideline AdherenceNon-financial Conflicts Of InterestPharmaceutical Cost Analysis
OBJECTIVE: To assess financial conflicts of interest (COI) and nonfinancial COI among psoriatic arthritis (PsA) clinical practice guideline (CPG) authors in Japan and the US, and to evaluate the quality of evidence and strength of recommendations of PsA CPGs. METHODS: We performed a retrospective analysis using payment data from major Japanese pharmaceutical companies and the US Open Payments Database from 2016 to 2018. All authors of PsA CPGs issued by the Japanese Dermatological Association (JDA) and American College of Rheumatology (ACR) were included. RESULTS: Of 23 CPG authors in Japan, 21 (91.3%) received at least 1 payment, with a combined total of $3,335,413 between 2016 and 2018. Regarding 25 US authors, 21 (84.0%) received at least 1 payment, with a combined total of $4,081,629 during the same period. The 3-year combined mean ± SD payment per author was $145,018 ± $114,302 in Japan and $162,825 ± $259,670 in the US. A total of 18 authors (78.3%) of the JDA PsA CPG and 12 authors (48.0%) of the ACR PsA CPG had undisclosed financial COI worth $474,663 and $218,501, respectively. The percentage of citations with at least 1 CPG author relative to total citations was 3.4% in Japan and 33.6% in the US. In sum, 71.4% and 88.8% of recommendations for PsA in the JDA and ACR were supported by low or very low quality of evidence. CONCLUSION: More rigorous cross-checking of information disclosed by pharmaceutical companies and self-reported by physicians and more stringent and transparent COI policies are necessary.
32
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
Richard G. Langley, Boni E. Elewski, Mark Lebwohl et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Dermatology, Immunology +14
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim Papp, Andrew Blauvelt, Michael Bukhalo et al. · New England Journal of Medicine · 2017 · 511 citations · Full text